Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
SDHB mutation
SDHx mutation
PRRT
metastatic pheochromocytoma/paraganglioma
somatostatin receptor 2
somatostatin receptor–based therapies
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
18 09 2023
18 09 2023
Historique:
received:
25
12
2022
medline:
19
9
2023
pubmed:
23
3
2023
entrez:
22
3
2023
Statut:
ppublish
Résumé
Pheochromocytomas and paragangliomas (PPGLs) with pathogenic mutations in the succinate dehydrogenase subunit B (SDHB) are associated with a high metastatic risk. Somatostatin receptor 2 (SSTR2)-dependent imaging is the most sensitive imaging modality for SDHB-related PPGLs, suggesting that SSTR2 expression is a significant cell surface therapeutic biomarker of such tumors. Exploration of the relationship between SSTR2 immunoreactivity and SDHB immunoreactivity, mutational status, and clinical behavior of PPGLs. Evaluation of SSTR-based therapies in metastatic PPGLs. Retrospective analysis of a multicenter cohort of PPGLs at 6 specialized Endocrine Tumor Centers in Germany, The Netherlands, and Switzerland. Patients with PPGLs participating in the ENSAT registry were included. Clinical data were extracted from medical records, and immunohistochemistry (IHC) for SDHB and SSTR2 was performed in patients with available tumor tissue. Immunoreactivity of SSTR2 was investigated using Volante scores. The main outcome measure was the association of SSTR2 IHC positivity with genetic and clinical-pathological features of PPGLs. Of 202 patients with PPGLs, 50% were SSTR2 positive. SSTR2 positivity was significantly associated with SDHB- and SDHx-related PPGLs, with the strongest SSTR2 staining intensity in SDHB-related PPGLs (P = .01). Moreover, SSTR2 expression was significantly associated with metastatic disease independent of SDHB/SDHx mutation status (P < .001). In metastatic PPGLs, the disease control rate with first-line SSTR-based radionuclide therapy was 67% (n = 22, n = 11 SDHx), and with first-line "cold" somatostatin analogs 100% (n = 6, n = 3 SDHx). SSTR2 expression was independently associated with SDHB/SDHx mutations and metastatic disease. We confirm a high disease control rate of somatostatin receptor-based therapies in metastatic PPGLs.
Identifiants
pubmed: 36946182
pii: 7083389
doi: 10.1210/clinem/dgad166
pmc: PMC10505550
doi:
Substances chimiques
Receptors, Somatostatin
0
somatostatin receptor 2
D73QL0OMU2
Succinate Dehydrogenase
EC 1.3.99.1
SSTR2 protein, human
0
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2676-2685Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.
Références
Cancers (Basel). 2019 Jun 28;11(7):
pubmed: 31261748
Gut. 2021 Sep;70(9):1768-1781
pubmed: 33692095
J Surg Oncol. 2017 Mar;115(4):425-434
pubmed: 28166370
Mod Pathol. 2007 Nov;20(11):1172-82
pubmed: 17873898
Int J Endocrinol. 2015;2015:138573
pubmed: 25883647
Mod Pathol. 2015 Jun;28(6):807-21
pubmed: 25720320
Front Neuroendocrinol. 1999 Jul;20(3):157-98
pubmed: 10433861
Acta Oncol. 2007;46(6):723-34
pubmed: 17653893
Q J Nucl Med Mol Imaging. 2008 Dec;52(4):334-40
pubmed: 18480742
Neuroendocrinology. 2010;91(3):268-78
pubmed: 20389030
Endocr J. 2003 Oct;50(5):507-13
pubmed: 14614206
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1223-30
pubmed: 25822655
J Hypertens. 2020 Aug;38(8):1443-1456
pubmed: 32412940
Eur J Cancer. 2022 Jul;169:32-41
pubmed: 35500459
J Clin Oncol. 2011 Jun 10;29(17):2416-23
pubmed: 21555692
Endocr Relat Cancer. 2019 Nov;26(11):R627-R652
pubmed: 31561209
Endocr Relat Cancer. 2016 Dec;23(12):899-908
pubmed: 27679736
Clin Endocrinol (Oxf). 2019 Dec;91(6):718-727
pubmed: 31569282
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112-2137
pubmed: 31254038
Endocr Relat Cancer. 2018 Oct 05;25(12):993-1004
pubmed: 30288966
Nat Rev Cancer. 2014 Feb;14(2):108-19
pubmed: 24442145
Clin Cancer Res. 2015 Sep 1;21(17):3888-95
pubmed: 25873086
Hum Pathol. 2019 Apr;86:66-75
pubmed: 30529752
Clin Endocrinol (Oxf). 2008 Jun;68(6):850-7
pubmed: 18031328
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3278-3287
pubmed: 28605448
Horm Metab Res. 2012 May;44(5):411-4
pubmed: 22566197
BMC Cancer. 2014 Jul 21;14:523
pubmed: 25048685
Eur J Nucl Med. 2001 Jul;28(7):836-46
pubmed: 11504080
Lancet Oncol. 2009 Aug;10(8):764-71
pubmed: 19576851
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Head Neck. 2013 Dec;35(12):E391-6
pubmed: 23606330
J Clin Endocrinol Metab. 2023 Sep 18;108(10):2676-2685
pubmed: 36946182
ESMO Open. 2021 Aug;6(4):100171
pubmed: 34139487
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Eur J Endocrinol. 2021 Jun 05;185(1):179-191
pubmed: 33983135
Med Oncol. 2016 May;33(5):47
pubmed: 27059363
J Clin Endocrinol Metab. 2020 Oct 1;105(10):
pubmed: 32750708
Cancers (Basel). 2019 Oct 08;11(10):
pubmed: 31597347
Cancer Cell. 2017 Feb 13;31(2):181-193
pubmed: 28162975
J Nucl Med. 2019 Mar;60(3):369-376
pubmed: 30030341
Theranostics. 2023 Jan 1;13(1):278-294
pubmed: 36593963
Ann Surg Oncol. 2020 May;27(5):1338-1347
pubmed: 32112213
Curr Opin Endocrinol Diabetes Obes. 2021 Jun 1;28(3):283-290
pubmed: 33764930
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
Cancer Imaging. 2016 Aug 17;16(1):22
pubmed: 27535829
Front Endocrinol (Lausanne). 2021 Mar 29;12:625312
pubmed: 33854479
Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15879-84
pubmed: 19717419
Eur J Endocrinol. 2019 Jul;181(1):45-53
pubmed: 31067510
Nucl Med Mol Imaging. 2020 Feb;54(1):48-52
pubmed: 32206131
J Clin Endocrinol Metab. 2019 Jun 1;104(6):2367-2374
pubmed: 30715419
Endocr Connect. 2020 Oct;9(9):864-873
pubmed: 32784267
Endocr Rev. 2022 Mar 9;43(2):199-239
pubmed: 34147030
Eur J Cancer. 2012 Jul;48(11):1739-49
pubmed: 22036874
EJNMMI Res. 2019 Feb 6;9(1):13
pubmed: 30725219
Mol Imaging Biol. 2011 Aug;13(4):769-75
pubmed: 20700766
Hum Pathol. 2015 Mar;46(3):390-6
pubmed: 25554089
Endocr Relat Cancer. 2019 May;26(5):539-550
pubmed: 30893643
Cancers (Basel). 2019 Jun 11;11(6):
pubmed: 31212687
J Clin Endocrinol Metab. 2022 Nov 23;107(11):2963-2972
pubmed: 35973976
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Endocr Relat Cancer. 2022 May 09;29(6):285-306
pubmed: 35324454